Split renal function in patients with hypertension following continued captopril treatment
The three different methods to evaluate the alterations of split renal function following continued captopril treatment were studied in patients with hypertension. Five patients had unilateral and 2 had bilateral renal artery stenosis, and 13 had normal renal arteries. The studies were performed the day prior to receiving captopril (baseline), and 6th or 7th day following continued captorpril treatment (37.5mg or 75mg/day): Split effective renal plasma flow (ERPF) and glomerular filtration rate (GFR) after injections of I-131 iodohippuran and Tc-99m DTPA were measured respectively by the methods using kidney counting corrected for depth and dose, described by Schlegel and Gates. And Tc-99m DMSA uptake was also evaluated qualitatively. In most of patients with renal artery stenosis, split GFR and Tc-99m DMSA uptake in the affected kidney were markedly decreased 6th or 7th day following continued captorpril treatment. These findings suggest that the captopril induced alterations of split renal function may be of importance for the diagnosis of renovascular hypertension. For this purpose, split GFR determination and Tc-99m DMSA study are more useful than split ERPF determination.
- Research Organization:
- Kanazawa Univ. Hospital, Kanazawa
- OSTI ID:
- 5973986
- Report Number(s):
- CONF-850611-; TRN: 87-039299
- Journal Information:
- J. Nucl. Med.; (United States), Vol. 26:5; Conference: 32. annual meeting of the Society of Nuclear Medicine, Houston, TX, USA, 2 Jun 1985
- Country of Publication:
- United States
- Language:
- English
Similar Records
Captopril induced renographic alteration in unilateral renal artery stenosis
Renovascular hypertension identified by captopril-induced changes in the renogram
Related Subjects
59 BASIC BIOLOGICAL SCIENCES
ENZYME INHIBITORS
BIOLOGICAL EFFECTS
DIAGNOSTIC USES
UPTAKE
HYPERTENSION
DIAGNOSIS
KIDNEYS
BLOOD FLOW
DYNAMIC FUNCTION STUDIES
ISCHEMIA
ANTIHYPERTENSIVE AGENTS
CHEMOTHERAPY
COMPARATIVE EVALUATIONS
DTPA
HIPPURAN
RADIOPHARMACEUTICALS
RESPONSE MODIFYING FACTORS
TECHNETIUM 99
THERAPY
VASCULAR DISEASES
AMINO ACIDS
BETA DECAY RADIOISOTOPES
BETA-MINUS DECAY RADIOISOTOPES
BODY
CARBOXYLIC ACIDS
CARDIOVASCULAR AGENTS
CARDIOVASCULAR DISEASES
CHELATING AGENTS
CONTRAST MEDIA
DISEASES
DRUGS
HOURS LIVING RADIOISOTOPES
INTERMEDIATE MASS NUCLEI
ISOMERIC TRANSITION ISOTOPES
ISOTOPES
LABELLED COMPOUNDS
NUCLEI
ODD-EVEN NUCLEI
ORGANIC ACIDS
ORGANIC COMPOUNDS
ORGANS
RADIOISOTOPES
RADIOPROTECTIVE SUBSTANCES
SYMPTOMS
TECHNETIUM ISOTOPES
USES
YEARS LIVING RADIOISOTOPES
550601* - Medicine- Unsealed Radionuclides in Diagnostics
551001 - Physiological Systems- Tracer Techniques